# 510(k) Summary

# BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \star }$ Amplified DNA Assay on the BD Viper LT System

# Applicant

BD Diagnostic Systems 7 Loveton Circle Sparks, MD 21152

# Establishment Registration No. 1 1 19779

Contact Person

Sherma Winston, M.S., RAC tel. 410-316-4145 fax. 410-316-4188 sherma_winston@bd.com

# Summary Date

May 16, 2014

Proprietary Name

BD ProbeTec™ Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \mathbf { x } }$ Amplified DNA Assay

# Generic Name

DNA probe, nucleic acid amplification, Chlamydia

# Classification Classification Name Regulation Number Product Code

Class I   
Chlamydia serological reagents   
866.3120   
MKZ

# Predicate Device

The BD ProbeTec Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \mathbf { x } }$ Amplified DNA Assay (BD ProbeTec CTQ Assay) was cleared for use with the predicate BD Viper System in extracted mode via K081824.

# Device Description

The BD ProbeTec CTQ Assay is based on the simultaneous amplification and detection of target DNA using amplification primers and a fluorescently-labeled detector probe The reagents for strand displacement amplification (SDA) are dried in two separate disposable microwells: the Priming Microwell contains the amplification primers, fluorescently-labeled detector probe, nucleotides and other reagents necessary for amplification, while the Amplification Microwell contains the two enzymes (a DNA polymerase and a restriction endonuclease) that are required for SDA. In alignment with the FDA Guidance Document, "Assay Migration Studies for In Vitro Diagnostic Devices, Guidance for Industry and FDA Staff", April 25, 2013 the BD ProbeTec CTQ Assay is being migrated from the existing BD Viper System operating in extracted mode (Viper XTR) to the new BD Viper LT System.

# BD ProbeTecTM Chlamydia trachomatis $( \mathbf { C T } ) \mathbf { Q } ^ { x }$ Amplified DNA Assay on the BD Viper LT System

The BD Viper LT System is a table-top instrument that is designed to be fully contained on a standard laboratory bench-top. The system performs automated extraction of nucleic acids from multiple specimen types in addition to amplification and detection of target nucleic acid sequences when utilized with legally marketed in vitro diagnostic assays.

# Intended Use

The BD ProbeTec Chlamydia trachomatis (CT) $\mathsf { Q } ^ { \mathsf { x } }$ Amplified DNA Assay when tested with either the BD ViperTM System in Extracted Mode or the BD ViperTM LT System, uses Strand Displacement Amplification technology for the direct, qualitative detection of Chlamydia trachomatis DNA in clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens (both UPT and Neat). The assay is also intended for use with gynecological specimens collected in BD SurePath™ Preservative Fluid or PreservCyt™ Solution using an aliquot that is removed prior to processing for either the BD SurePath or ThinPrepTM Pap test. The assay is indicated for use with asymptomatic and symptomatic individuals to aid in the diagnosis of chlamydial urogenital disease.

# Comparison to Predicate Device

A comparison of the BD ProbeTec CTQ Assay on the BD Viper LT System with the predicate BD Viper System is summarized below.

# BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \star }$ Amplified DNA Assay on the BD Viper LT System

Table 1 Comparison to Predicate Device   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>BD ProbeTec CTQ Assay onBD Viper Systemi              (K081824)</td><td rowspan=1 colspan=1>BD ProbeTec CTQ Assay onBD Viper LT System(K140446)</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>I</td></tr><tr><td rowspan=1 colspan=1>Regulation Specialty</td><td rowspan=1 colspan=1>Microbiology</td><td rowspan=1 colspan=1>Microbiology</td></tr><tr><td rowspan=1 colspan=1>Assay Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Qualitative</td></tr><tr><td rowspan=1 colspan=1>Type of Assay</td><td rowspan=1 colspan=1>Molecular NAAT</td><td rowspan=1 colspan=1>Molecular NAAT</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The BD ProbeTec CT Q* AmplifiedDNA Assay when tested with the BDViperTM System in Extracted Mode,uses Strand DisplacementAmplification technology for thedirect, qualitative detection ofChlamydia trachomatis DNA inclinician- collected femaleendocervical and male urethral swabspecimens, patient-collected vaginalswab specimens (in a clinicalsetting), and male and female urinespecimens. The assay is indicated foruse with asymptomatic andsymptomatic individuals to aid in thediagnosis of chlamydial urogenitaldisease.</td><td rowspan=1 colspan=1>The BD ProbeTec Chlamydiatrachomatis (CT) Q* Amplified DNAAssay when tested with either theBD ViperTM System in ExtractedMode or the BD Viper™M LT System,uses Strand DisplacementAmplification technology for thedirect, qualitative detection ofChlamydia trachomatis DNA inclinician- collected femaleendocervical and male urethral swabspecimens, patient-collected vaginalswab specimens (in a clinicalsetting), and male and female urinespecimens (both UPT and Neat). Theassay is also intended for use withgynecological specimens collected inBD SurePathT Preservative Fluid orPreservCytTM Solution using analiquot that is removed prior toprocessing for either the BDSurePath or ThinPrepTM Pap test.The assay is indicated for use withasymptomatic and symptomaticindividuals to aid in the diagnosis ofchlamydial urogenital disease.</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Strand Displacement Amplification(SDA)</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Specimen Types</td><td rowspan=1 colspan=1>Female specimens:endocervical swabpatient-collected vaginal swabneat urineUPT urineMale specimens:</td><td rowspan=1 colspan=1>Female specimens:endocervical swabpatient-collected vaginal swabneat urineUPT urineLBC specimens collected in SurePathPreservative Fluid</td></tr></table>

# 510(k) Summary

# BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \pm }$ Amplified DNA Assay on the BD Viper LT System

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>BD ProbeTec CTQ Assay onBD Viper System(K081824)</td><td rowspan=1 colspan=1>BD ProbeTec CTQ Assay onBD Viper LT System(K140446)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>urethral swabneat urineUPT urine</td><td rowspan=1 colspan=1>LBC specimens collected in PreservCytSolutionMale specimens:urethral swabneat urineUPT urine</td></tr><tr><td rowspan=1 colspan=3>Priming Microwell</td></tr><tr><td rowspan=1 colspan=1>Primers</td><td rowspan=1 colspan=1>Region of cryptic CT plasmid</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detector</td><td rowspan=1 colspan=1>Linear, analyte-specific Detector Probe• Fluorescein (fluorophore)•  Dabcyl (quencher)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Nucleotides</td><td rowspan=1 colspan=1>4 nucleotides required for SDA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Non-specific reagents andcofactors</td><td rowspan=1 colspan=1>Buffering components, magnesium ions,salt and stabilizing reagents</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Amplification Microwell</td></tr><tr><td rowspan=1 colspan=1>Restriction Enzyme</td><td rowspan=1 colspan=1>BsoBI restriction enzyme</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Polymerase</td><td rowspan=1 colspan=1>Bst DNA polymerase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Non-specific reagents andcofactors</td><td rowspan=1 colspan=1>Buffering components, magnesium ions,salt and stabilizing reagents</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Buffer</td><td rowspan=1 colspan=1>Bicine-potassium hydroxide-based</td><td rowspan=1 colspan=1>Same</td></tr></table>

# BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \star }$ Amplified DNA Assay on the BD Viper LT System

# Analytical Performance Characteristics

The BD ProbeTec CTQ Assay formulation for the BD Viper LT System has not changed from that used with the BD Viper System in extracted mode. Studies were conducted to support analytical performance of the BD Viper LT System.

# System Contamination

A study was conducted to evaluate the risk of producing a false positive result in either the same run on the BD Viper LT System or in a subsequent run. Negative and positive samples were tested on each of three BD Viper LT Systems. Negative samples consisted of $\mathbf { Q } ^ { x }$ Swab Diluent or LBC Specimen Dilution Tube with LBC Specimen Matrix (PreservCyt LBC media). Positive samples consisted of a representative analyte (at $1 0 ^ { 5 } \mathrm { C T } \mathrm { E B / m L }$ spiked into $\mathbf { Q } ^ { x }$ Swab Diluent or LBC Specimen Dilution Tube with LBC Specimen Matrix. The overall rate of contamination (i.e., with alternating columns of positive and negative samples and a prevalence of $50 \%$ was $0 . 3 2 \%$ (2/630) for $\mathbf { Q } ^ { x }$ Swab Diluent and $0 . 0 \%$ (0/630) for LBC Specimen Matrix. Contamination rates across the three BD Viper LT Systems are summarized in Table 2.

Table 2 System Contamination   

<table><tr><td rowspan=2 colspan=1>BD ViperLTSystem</td><td rowspan=1 colspan=3>Q° Sample Diluent</td><td rowspan=1 colspan=3>LBC Specimen Matrix</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>PositiveResults</td><td rowspan=1 colspan=1>PercentPositive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>PositiveResults</td><td rowspan=1 colspan=1>PercentPositive</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00%</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>.2</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.48%</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.48%</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>630</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.32%</td><td rowspan=1 colspan=1>630</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00%</td></tr></table>

# BD ProbeTec™M Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \pmb { \tau } }$ Amplified DNA Assay on the BD Viper LT System

# Clinical Performance Characteristics

The BD ProbeTec CTQ Assay formulation for the BD Viper LT System has not changed from that used with the BD Viper System in Extracted Mode. The following studies were conducted to support clinical performance of the BD Viper LT System.

Clinician-collected BD SurePath and PreservCyt specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female $\mathsf { Q } ^ { x }$ UPT urine specimens were collected from 653 female subjects and 170 male subjects attending OB/GYN, sexually transmitted disease (STD) and family planning clinics at four geographically diverse clinical sites in North America. Subjects were classified as symptomatic if symptoms were reported by the subject. The final data analysis included 617 compliant female subjects and 167 compliant male subjects. All specimens were shipped to BD on cold packs for specimen screening, aliquoting, and comparison panel assembly.

Each comparison panel consisted of randomly chosen positive and negative specimens (based on BD Viper System in extracted mode reference results). The positive and negative specimens were randomized within the panel, and labeled such that the instrument user was blinded to the specimen results. Panels were identical across all of the BD Viper LT test sites. The blinded comparison panels were sent to the -3 external sites for testing on the BD Viper LT System and one internal site for testing using the BD Viper System in extracted mode with the BD ProbeTec CTQ Assay.

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Positive Percent Agreement</td><td rowspan=1 colspan=2>Negative Percent Agreement</td></tr><tr><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Percent</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Percent</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=16 colspan=1>Female</td><td rowspan=4 colspan=1>Vaginal Swab</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>100.0% (46/46)</td><td rowspan=1 colspan=1>(92.3%, 100.0%)</td><td rowspan=1 colspan=1>95.0% (57/60)</td><td rowspan=1 colspan=1>(86.3%, 98.3%)</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>100.0% (46/46)</td><td rowspan=1 colspan=1>(92.3%, 100.0%)</td><td rowspan=1 colspan=1>98.3% (59/60)</td><td rowspan=1 colspan=1>(91.1%, 99.7%)</td></tr><tr><td rowspan=1 colspan=1>c</td><td rowspan=1 colspan=1>100.0% (46/46)</td><td rowspan=1 colspan=1>(92.3%, 100.0%)</td><td rowspan=1 colspan=1>91.7% (55/60)</td><td rowspan=1 colspan=1>(81.9%, 96.4%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100.0% (138/138)</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>95.0% (171/180)</td><td rowspan=1 colspan=1>(90.6%, 98.3%)</td></tr><tr><td rowspan=4 colspan=1>Q&#x27;UPT</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>97.9% (46/47)</td><td rowspan=1 colspan=1>(88.9%, 99.6%)</td><td rowspan=1 colspan=1>98.3% (58/59)</td><td rowspan=1 colspan=1>(91.0%, 99.7%)</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>97.9% (46/47)</td><td rowspan=1 colspan=1>(88.9%, 99.6%)</td><td rowspan=1 colspan=1>100.0% (59/59)</td><td rowspan=1 colspan=1>(93.9%, 100.0%)</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>95.7% (45/47)</td><td rowspan=1 colspan=1>(85.8%, 98.8%)</td><td rowspan=1 colspan=1>98.3% (58/59)</td><td rowspan=1 colspan=1>(91.0%, 99.7%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>97.2% (137/141)</td><td rowspan=1 colspan=1>(92.2%, 100.0%)</td><td rowspan=1 colspan=1>98.9% (175/177)</td><td rowspan=1 colspan=1>(96.6%, 100.0%)</td></tr><tr><td rowspan=4 colspan=1>BD SurePath</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>100.0% (39/39)</td><td rowspan=1 colspan=1>(91.0%, 100.0%)</td><td rowspan=1 colspan=1>97.0% (65/67)</td><td rowspan=1 colspan=1>(89.8%, 99.2%)</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>100.0% (39/39)</td><td rowspan=1 colspan=1>(91.0%, 100.0%)</td><td rowspan=1 colspan=1>97.0% (65/67)</td><td rowspan=1 colspan=1>(89.8%, 99.2%)</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>100.0% (39/39)</td><td rowspan=1 colspan=1>(91.0%, 100.0%)</td><td rowspan=1 colspan=1>97.0% (65/67)</td><td rowspan=1 colspan=1>(89.8%, 99.2%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100.0% (117/117)</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>97.0% (195/201)</td><td rowspan=1 colspan=1>(93.0%, 100.0%)</td></tr><tr><td rowspan=4 colspan=1>PreservCyt</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>97.5% (39/40)</td><td rowspan=1 colspan=1>(87.1%, 99.6%)</td><td rowspan=1 colspan=1>97.0% (64/66)</td><td rowspan=1 colspan=1>(89.6%, 99.2%)</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>95.0% (38/40)</td><td rowspan=1 colspan=1>(83.5%, 98.6%).</td><td rowspan=1 colspan=1>98.5% (65/66)</td><td rowspan=1 colspan=1>(91.9%, 99.7%)</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>95.0% (38/40)</td><td rowspan=1 colspan=1>(83.5%, 98.6%)</td><td rowspan=1 colspan=1>98.5% (65/66)</td><td rowspan=1 colspan=1>(91.9%, 99.7%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>95.8% (115/120)</td><td rowspan=1 colspan=1>(89.2%, 100.0%)</td><td rowspan=1 colspan=1>98.0% (194/198)</td><td rowspan=1 colspan=1>(96.0%, 99.5%)</td></tr><tr><td rowspan=4 colspan=1>Male</td><td rowspan=4 colspan=1>Q&#x27; UPT</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>97.9% (47/48)</td><td rowspan=1 colspan=1>(89.1%, 99.6%)</td><td rowspan=1 colspan=1>100.0% (65/65)</td><td rowspan=1 colspan=1>(94.4%, 100.0%)</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>95.8% (46/48)</td><td rowspan=1 colspan=1>(86.0%, 98.8%)</td><td rowspan=1 colspan=1>100.0% (65/65)</td><td rowspan=1 colspan=1>(94.4%, 100.0%)</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>95.8% (46/48)</td><td rowspan=1 colspan=1>(86.0%, 98.8%)</td><td rowspan=1 colspan=1>98.5% (64/65)</td><td rowspan=1 colspan=1>(91.8%, 99.7%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>96.5% (139/144)</td><td rowspan=1 colspan=1>(92.4%, 100.0%)</td><td rowspan=1 colspan=1>99.5% (194/195)</td><td rowspan=1 colspan=1>(98.5%, 100.0%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>97.9% (646/660)</td><td rowspan=1 colspan=1>(96.0%, 99.4%)</td><td rowspan=1 colspan=1>97.7% (929/951)</td><td rowspan=1 colspan=1>(96.3%, 98.8%)</td></tr></table>

P  so  cd spoad p bu da

# 510(k) Summary

# BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \mathbf { r } }$ Amplified DNA Assay on the BD Viper LT System

# Reproducibility

Reproducibility of the BD Viper LT System using the BD ProbeTec CTQ Amplified DNA Assay was evaluated at three test sites (two external clinical sites and one internal site) on one BD Viper LT System per site. Panels comprised of three levels of CT and GC organisms seeded into LBC specimen matrix $\mathrm { 0 . 5 ~ m L }$ spiked into LBC Dilution Tubes for the BD ProbeTec $\boldsymbol { \mathrm { Q } } ^ { x }$ Amplified DNA Assays), vaginal matrix in $\boldsymbol { \mathrm { Q } } ^ { x }$ Swab Diluent (containing a clean male urethral swab), and urine specimen matrix (in $\mathsf { Q } ^ { x }$ UPT). CT and GC organisms were spiked into each specimen matrix. Uninoculated LBC specimen matrix, vaginal matrix in $\mathsf { Q } ^ { x }$ diluent, and urine matrix were used as negative samples. Two operators per site performed the BD Viper LT reproducibility study. Both operators ran one panel each day, over a total of eight days. A total of sixteen runs, each composed of 8 LBC, 8 swab and 8 UPT panel members described above were performed at each of two external BD Viper LT test sites and one internal BD Viper LT test site. The data are summarized in Table 4.

<table><tr><td rowspan=1 colspan=5></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Runwithin Day</td><td rowspan=1 colspan=2>Between Daywithin Site</td><td rowspan=1 colspan=2>Between Site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SpecimenType</td><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>% Correct</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LBC</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>99.0% (95/96)</td><td rowspan=1 colspan=1>(94.3 - 99.8%)</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>104.7</td><td rowspan=1 colspan=1>718.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>49.1%</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>47.4%</td><td rowspan=1 colspan=1>105.2</td><td rowspan=1 colspan=1>722.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>41.7% (40/96)</td><td rowspan=1 colspan=1>(32.3 - 51.7%)</td><td rowspan=1 colspan=1>565.0</td><td rowspan=1 colspan=1>533.2</td><td rowspan=1 colspan=1>94.4%</td><td rowspan=1 colspan=1>226.5</td><td rowspan=1 colspan=1>40.1%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>579.3</td><td rowspan=1 colspan=1>102.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>100.0% (96/96)</td><td rowspan=1 colspan=1>(96.2 - 100.0%)</td><td rowspan=1 colspan=1>1435.3</td><td rowspan=1 colspan=1>372.3</td><td rowspan=1 colspan=1>25.9%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>85.2</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>86.4</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>391.6</td><td rowspan=1 colspan=1>27.3%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>98.9% (93/94)</td><td rowspan=1 colspan=1>(94.2 - 99.8%)</td><td rowspan=1 colspan=1>1752.4</td><td rowspan=1 colspan=1>241.0</td><td rowspan=1 colspan=1>13.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>36.1</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>243.7</td><td rowspan=1 colspan=1>13.9%</td></tr><tr><td rowspan=1 colspan=1>Swab</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>100.0% (96/96)</td><td rowspan=1 colspan=1>(96.2 - 100.0%)</td><td rowspan=1 colspan=1>22.1</td><td rowspan=1 colspan=1>28.6</td><td rowspan=1 colspan=1>129.3%</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>39.5%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>22.5%</td><td rowspan=1 colspan=1>30.3</td><td rowspan=1 colspan=1>137.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>24.0% (23/96)</td><td rowspan=1 colspan=1>(16.5 - 33.4%)</td><td rowspan=1 colspan=1>974.0</td><td rowspan=1 colspan=1>716.7</td><td rowspan=1 colspan=1>73.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>105.1</td><td rowspan=1 colspan=1>10.8%</td><td rowspan=1 colspan=1>724.4</td><td rowspan=1 colspan=1>74.4%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>95.8% (91/95)</td><td rowspan=1 colspan=1>(89.7 - 98.4%)</td><td rowspan=1 colspan=1>1603.8</td><td rowspan=1 colspan=1>535.8</td><td rowspan=1 colspan=1>33.4%</td><td rowspan=1 colspan=1>115.0</td><td rowspan=1 colspan=1>7.2%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>548.0</td><td rowspan=1 colspan=1>34.2%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>100.0% (96/96)</td><td rowspan=1 colspan=1>(96.2 - 100.0%)</td><td rowspan=1 colspan=1>1780.6</td><td rowspan=1 colspan=1>320.3</td><td rowspan=1 colspan=1>18.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>59.6</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>52.2</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>330.0</td><td rowspan=1 colspan=1>18.5%</td></tr><tr><td rowspan=1 colspan=1>UPT</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>99.0% (95/96)</td><td rowspan=1 colspan=1>(94.3 - 99.8%)</td><td rowspan=1 colspan=1>21.5</td><td rowspan=1 colspan=1>171.4</td><td rowspan=1 colspan=1>797.4%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>27.0%</td><td rowspan=1 colspan=1>171.5</td><td rowspan=1 colspan=1>797.9%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>32.3% (31/96)</td><td rowspan=1 colspan=1>(23.8 - 42.2%)</td><td rowspan=1 colspan=1>678.3</td><td rowspan=1 colspan=1>578.6</td><td rowspan=1 colspan=1>85.3%</td><td rowspan=1 colspan=1>276.0</td><td rowspan=1 colspan=1>40.7%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>641.1</td><td rowspan=1 colspan=1>94.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>99.0% (95/96)</td><td rowspan=1 colspan=1>(94.3 - 99.8%)</td><td rowspan=1 colspan=1>1549.4</td><td rowspan=1 colspan=1>432.5</td><td rowspan=1 colspan=1>27.9%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>85.9</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>441.0</td><td rowspan=1 colspan=1>28.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>100.0% (96/96)</td><td rowspan=1 colspan=1>(96.2 - 100.0%)</td><td rowspan=1 colspan=1>1747.0</td><td rowspan=1 colspan=1>223.9</td><td rowspan=1 colspan=1>12.8%</td><td rowspan=1 colspan=1>133.5</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>22.5</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>261.6</td><td rowspan=1 colspan=1>15.0%</td></tr></table>

we L    o s e

# 510(k) Summary

# BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \star }$ Amplified DNA Assay on the BD Viper LT System

# Conclusions

The analytical and clinical study results for the BD ProbeTec Chlamydia trachomatis (CT) Qx Amplified DNA Assay tested on the BD Viper LT System support the determination of substantial equivalence in accordance with the intended use as stated in the product labeling.

Becton, Dickinson and Company   
Sherma Winston, M.S., RAC   
7 Loveton Circle   
Sparks, MD 21152

Re: K140446 Trade/Device Name: BD ProbeTecTM Chlamydia trachomatis (CT) $\mathbf { Q } ^ { \mathbf { x } }$ Amplified DNA Assay Regulation Number: 21 CFR 866.3120 Regulation Name: Chlamydia serological reagents Regulatory Class: I Product Code: MKZ Dated: February 20, 2014 Received: February 21, 2014

Dear Ms. Winston:

We have reviewed your Section $\mathfrak { s l o } ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties.We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Tamara V. Feldblyum -S for

Sally Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Enclosure

# Indications for Use

510(k) Number: K140446

Device Name: BD ProbeTec™ Chlamydia trachomatis (CT) $\bumpeq$ Amplified DNA Assay

Indications for Use:

The BD Probe Tec Chlamydia trachomatis (CT) $\ b { \sf Q } ^ { \star }$ Amplified DNA Assay, when tested with either the BD Viper ™ System in Extracted Mode or the BD Viper™ LT System, uses Strand Displacement Amplification technology for the direct, qualitative detection of Chlamydia trachomatis DNA in clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens (both UPT and Neat). The assay is also intended for use with gynecological specimens collected in BD SurePath ™ Preservative Fluid or PreservCyt™ Solution using an aliquot that is removed prior to processing for either the BD SurePath or ThinPrep ™m Pap test. The assay is indicated for use with asymptomatic and symptomatic individuals to aid in the diagnosis of chlamydial urogenital disease.

Prescription Use _ Over-The-Counter Use AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of Center for Devices and Radiological Health (CDRH)